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Background
A 22 year old male was diagnosed with clinical T2 squa-
mous cell carcinoma of the lateral oral tongue. He under-
went partial glossectomy with elective neck dissection of
ipsilateral cervical nodes levels I-IV. Pathology showed a
2.1cm primary tumor with clear margins to 5mm, 1.6cm
depth of invasion, one of 23 lymph nodes with a 3.5mm
focus of involvement at level II, sans extra-capsular exten-
sion (pT2 pN1 M0).
Methods
Through an institutional research tissue protocol,
a primary cell line was successfully established. TIL were
simultaneously cultured and demonstrated tumor specific
IFN-g production. He completed a course of adjuvant
IMRT to 60Gy in the ipsilateral neck and 54Gy in the
contralateral neck within 12 weeks of surgery, without
complications.
Results
Three months following completion of radiation, bilateral
neck nodal recurrence was noted on scans and confirmed
by biopsy (month 6 of disease course, overall). He was
treated first line chemotherapy for recurrent disease dur-
ing months 7 to 10, progressing locally in the neck
through two multi-drug regimens (cisplatin/cetuximab/
5FU, carboplatin/docetaxel). He then enrolled on a Phase
Ib trial of combination anti-PD-1/anti-KIR during months
11 to 14 (BMS CA223-001, nivolumab/lirilumab), again
progressing locally in the bilateral neck. At month 15, an
individual patient compassionate treatment protocol was
approved (FDA IND #16279, PH&S IRB #14-323B), using
reduced-intensity Cy/Flu preparative lymphodepletion
followed by adoptive transfer of expanded autologous TIL
in conjunction with DC-targeted microvessicle DPV-001
intradermal vaccine (DRibbles) and imiquimod adjuvant,
with high-dose IL-2 support. Peripheral immune monitor-
ing was performed using whole blood time-course sam-
pling. Multi-spectral immunofluorescence with digital
image quantitative immunophenotyping of FFPE longitu-
dinal biopsy specimens was performed using the PerkinEl-
mer Vectra® platform. Data and results analysis will be
presented in poster format.
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